Press Resease

Overactive Bladder Treatment Market By Pharmacotherapy (Anticholinergic, Botox, and Others) and By Disease (Neurogenic Overactive Bladder and Idiopathic Overactive Bladder): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 23-Sep-2019 Category: Pharmaceutical Report Format : PDF Pages: 130 Report Code: ZMR-3682 Status : Published

Global overactive bladder treatment market expected to generate around USD 4,594 million by 2025, at a CAGR of around 3% between 2019 and 2025. Overactive bladder is a urological condition associated with urination problems and is also known as overactive bladder syndrome.

Description

The report covers a forecast and an analysis of the overactive bladder treatment market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the overactive bladder treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the overactive bladder treatment market on a global level.

In order to give the users a comprehensive view of the overactive bladder treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Overactive Bladder Treatment Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the overactive bladder treatment market by segmenting it based on pharmacotherapy, disease, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some major players involved in the overactive bladder treatment market are Macleods Pharmaceuticals, Allergan, Mylan, Endo International, Sanofi, Apotex, Johnson & Johnson, Aurobindo Pharma, Medtronic, Cogentix Medical, Astellas Pharma, Pfizer, Teva Pharmaceutical, Hisamitsu Pharmaceutical, and Intas Pharmaceuticals.

This report segments the global overactive bladder treatment market into:

Global Overactive Bladder Treatment Market: Pharmacotherapy Analysis

  • Botox
  • Anticholinergic
  • Others

Global Overactive Bladder Treatment Market: Disease Analysis

  • Idiopathic Overactive Bladder
  • Neurogenic Overactive Bladder
    • Overactive Bladder in Stroke
    • Parkinson’s Disease
    • Overactive Bladder in Multiple Sclerosis
    • Overactive Bladder in Spinal Cord
    • Overactive Bladder in Other Disorders

Global Overactive Bladder Treatment Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Overactive bladder treatment Market, 2016-2025 (USD Million)
    • 2.2. Overactive bladder treatment Market: Market Snapshot
  •  
  • Chapter 3. Overactive Bladder Treatment Market - Industry Analysis
    • 3.1. Overactive Bladder Treatment Market: Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of overactive bladder
      • 3.2.2. Growing geriatric population
      • 3.2.3. Rising neurological disorders
      • 3.2.4. Increasing government initiatives and awareness in developing nations
      • 3.2.5. Advanced R&D in the field of overactive bladder treatment
      • 3.2.6. Rising acute urinary tract infection cases
    • 3.3. Restraints
      • 3.3.1. Lack of awareness in underdeveloped nations
      • 3.3.2. Undesirable effects of current treatments
    • 3.4. Opportunity
      • 3.4.1. Evolving market
      • 3.4.2. Advanced technology
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by pharmacotherapy
      • 3.6.2. Market attractiveness analysis by disease
      • 3.6.3. Market attractiveness analysis by region
  •  
  • Chapter 4. Overactive Bladder Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global overactive bladder treatment market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launches
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Overactive Bladder Treatment Market - Pharmacotherapy Analysis
    • 5.1. Global overactive bladder treatment market overview: by pharmacotherapy
      • 5.1.1. Global overactive bladder treatment market share, by pharmacotherapy, 2018 and 2025
    • 5.2. Botox
      • 5.2.1. Global overactive bladder treatment market by botox, 2016-2025 (USD Million)
    • 5.3. Anticholinergic
      • 5.3.1. Global overactive bladder treatment market by anticholinergic, 2016-2025 (USD Million)
    • 5.4. Others
      • 5.4.1. Global overactive bladder treatment market by others, 2016-2025 (USD Million)
  •  
  • Chapter 6. Global Overactive Bladder Treatment Market - Disease Analysis
    • 6.1. Global overactive bladder treatment market overview: by disease
      • 6.1.1. Global overactive bladder treatment market share, by disease, 2018 and 2025
    • 6.2. Idiopathic Overactive Bladder
      • 6.2.1. Global overactive bladder treatment market by idiopathic overactive bladder, 2016-2025 (USD Million)
    • 6.3. Neurogenic Overactive Bladder
      • 6.3.1. Global overactive bladder treatment market by neurogenic overactive bladder, 2016-2025 (USD Million)
  •  
  • Chapter 7. Global Overactive Bladder Treatment Market - Regional Analysis
    • 7.1. Global overactive bladder treatment market overview: by region
      • 7.1.1. Global overactive bladder treatment market share, by region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America overactive bladder treatment market, 2016-2025 (USD Million)
      • 7.2.2. North America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
      • 7.2.3. North America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S. overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.2.4.2. The U.S. overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.2.5.2. Rest of North America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe overactive bladder treatment market, 2016-2025 (USD Million)
      • 7.3.2. Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
      • 7.3.3. Europe overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.3.4. The U.K.
        • 7.3.4.1. U.K. overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.3.4.2. U.K. overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.3.5.2. France overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.3.6.2. Germany overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.3.7.2. Rest of Europe overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific overactive bladder treatment market, 2016-2025 (USD Million)
      • 7.4.2. Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
      • 7.4.3. Asia Pacific overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.4.4.2. China overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.4.5.2. Japan overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.4.6.2. India overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America overactive bladder treatment market, 2016-2025 (USD Million)
      • 7.5.2. Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
      • 7.5.3. Latin America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.5.4.2. Brazil overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
      • 7.5.5. Rest of Latin America
        • 7.5.5.1. Rest of Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
        • 7.5.5.2. Rest of Latin America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa overactive bladder treatment market, 2016-2025 (USD Million)
      • 7.6.2. The Middle East and Africa overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
      • 7.6.3. The Middle East and Africa overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
  •  
  • Chapter 8. Company Profiles
    • 8.1. Macleods Pharmaceuticals
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Allergan
      • 8.2.1. overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Mylan
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Endo International
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Hisamitsu Pharmaceutical
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Developments
    • 8.6. Apotex
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Developments
    • 8.7. Johnson & Johnson
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Developments
    • 8.8. Aurobindo Pharma
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Developments
    • 8.9. Medtronic
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Developments
    • 8.10. Cogentix Medical
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Developments

Methodology

Free Analysis

Overactive bladder is a urological condition associated with urination problems and is also known as overactive bladder syndrome. Major symptoms include urgency in urination and change in urination frequency. It can cause various neurological diseases, such as Parkinson’s disease. Overactive bladder can affect anyone, irrespective of one’s age and gender.

The growing prevalence of overactive bladder, escalating geriatric population, and rising neurological disorders are driving the overactive bladder treatment market. Increasing incidences of Parkinson’s disease, overactive bladder in the spinal cord, rising disposable income, growing awareness regarding overactive bladder syndrome, and accelerating technological advancements for patient handling will further boost this market. Rising prevalence of diabetes, growing acute urinary tract infection, increasing consumption of caffeine and alcohol, and growing unhealthy lifestyles are also driving the overactive bladder treatment market. Moreover, flourishing healthcare infrastructure, increasing government initiatives, and growing number of doctor worldwide, developing innovative intravesical therapies, and active marketing activities by pharmaceutical giants are some other drivers stimulating the overactive bladder treatment market. However, the lack of awareness and adverse side-effects of current treatments may hinder this market.

Global Overactive Bladder Treatment Market

The overactive bladder treatment market is segmented on the basis of pharmacotherapy into botox, anticholinergic, and others. On the basis of disease, the overactive bladder treatment market includes neurogenic overactive bladder and idiopathic overactive bladder. Neurogenic overactive bladder is further divided into overactive bladder in stroke, Parkinson’s disease, overactive bladder in multiple sclerosis, overactive bladder in spinal cord, and overactive bladder in other disorders. The high adoption of technological advancements, increasing development of healthcare infrastructure, and rising government initiatives are stimulating the neurogenic overactive bladder segment.

North America dominated the overactive bladder treatment market in 2018 globally. About 11% of the total North American population suffered from overactive bladder complications in 2017. It accounted for 48% of the market share in terms of revenue. Growing prevalence of overactive bladders due to rising geriatric population, increasing diabetic patients, and rising acute urinary tract infection are contributing to the North American market. Europe held the second spot in the overactive bladder treatment market globally in 2018, due to the growing technological advancements and consistently developing hospital infrastructure. The Asia Pacific is expected to account for the fastest growth rate in the overactive bladder treatment market, owing to the huge population in China, India, and Japan.

Some major players involved in the overactive bladder treatment market are Macleods Pharmaceuticals, Allergan, Mylan, Endo International, Sanofi, Apotex, Johnson & Johnson, Aurobindo Pharma, Medtronic, Cogentix Medical, Astellas Pharma, Pfizer, Teva Pharmaceutical, Hisamitsu Pharmaceutical, and Intas Pharmaceuticals.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com